VANCOUVER, British Columbia and ORLANDO, Fla., Oct. 23, 2024 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced it will host a conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 8:30 a.m. ET. Participants can access the conference call via […]
VANCOUVER, British Columbia, Oct. 23, 2024 (GLOBE NEWSWIRE) — Nevada Lithium Resources Inc. (CSE: NVLH; OTCQB: NVLHF; FSE: 87K) (“Nevada Lithium” or the “Company”) is pleased to provide a technical update on its 2024 metallurgical program at its 100% owned Bonnie Claire Lithium project (the “Project” or “Bonnie Claire”), located in Nye County, Nevada. Nevada
MARYSVILLE, Ohio, Oct. 23, 2024 (GLOBE NEWSWIRE) — The Scotts Miracle-Gro Company (NYSE: SMG), the world’s leading marketer of branded consumer lawn and garden as well as indoor and hydroponic growing products, will release its fourth quarter financial results on Wednesday, November 6, 2024, prior to the opening of the U.S. financial markets. The Company
FARO® Technologies, Inc. (Nasdaq: FARO), a global leader in 4D digital reality solutions, today announced that after market close on Wednesday, November 6, 2024, it will release its financial results for the third quarter endedSeptember 30, 2024. In conjunction with the release,Peter Lau, President and Chief Executive Officer, and Matthew Horwath, Senior Vice President and
Cyclin E1 molecular glue degraders (MGDs) represent a potential novel therapeutic approach by directly and selectively targeting a frequently amplified non-enzymatic driver oncogene relevant in multiple solid tumors Cyclin E1 MGD inhibited tumor growth in CCNE1-amplified cancer models in vivoâ?¯ BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage
TORONTO, Oct. 23, 2024 (GLOBE NEWSWIRE) — CFA Societies Canada, Canada’s voice for professionalism in investment management and finance, announces the election of Jimmy Kwame Boateng, CFA, Frank Lachance, CFA, and Nilesh Paray, CFA, as members of its board of directors for a two-year term effective Tuesday, October 22, 2024. They will join re-elected members
OP-3136, a potent KAT6 inhibitor, demonstrated robust anti-tumor activity as a single agent, as well as synergy and enhanced anti-tumor activity in combination with palazestrant; IND submission expected before year end Palazestrant demonstrated combinability and enhanced tumor suppression with both everolimus and capivasertib SAN FRANCISCO, Oct. 23, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”
Preclinical data highlight company’s fourth discovery stage program, a novel potent and selective KRAS(ON) inhibitor Updated preclinical data from CGT6297, Cogent’s H1047R mutant-selective PI3Kα inhibitor demonstrates robust inhibition of downstream signaling and efficacy WALTHAM, Mass. and BOULDER, Colo., Oct. 23, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing
– Topline Data from 52-week Phase 3 Study Expected in Late 2025 – CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that enrollment is complete for the Phase 3 RISE UP study. This
Starget’s Smart Targeted Radioligand (STR) Theranostics Enable Precise Targeted Delivery of Highly Focused Molecular Radiation Directly to Cancer Cells while Minimizing Damage to Healthy Tissues Lead Program DOTA–PTR-58 Was Developed Using Starget’s Proprietary Peptide Backbone Dynamics Platform that Leverages Backbone Cyclic Innovations and In-Silico AI to Rapidly Design Highly Specific Ligands TEL AVIV, Israel and